ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Breaking News! The Second ADC Approved for Marketing in China
May 21, 2020According to the NMPA website on May 13, the marketing application for Brentuximab Vedotin Injection filed by Takeda Pharmaceutical in China has been reviewed and approved, to become the second ADC approved for marketing in China. -
Pfizer gets USFDA nod for XALKORI (crizotinib) to treat ALK-positive ALCL in children and young adults
January 15, 2021XALKORI is the first biomarker-driven therapy for relapsed or refractory ALCL in young people. -
FDA grants priority review for Pfizer’s Xalkori in paediatric ALCL
September 27, 2020Pfizer has secured priority review from the US Food and Drug Administration (FDA) for Xalkori (crizotinib) to treat relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) in children.
Pharma Sources Insight January 2025
